Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

CRISPR

CRISPR

Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...

What is Genetic Engineering?

What is Genetic Engineering?

In-vitro Mutagenesis

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...

RNA Editing

RNA Editing

RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

High serum transthyretin concentrations identify a low likelihood of advanced myocardial amyloid burden in suspected ATTR cardiomyopathy.

European journal of heart failure·2026

Same author

Association of high-sensitivity cardiac troponin T with all-cause and cardiovascular mortality in a mobile cohort of older adults aged 70 to 95 years - Results from the AugUR study.

American journal of preventive cardiology·2026

Same author

Differential effects of transcatheter edge-to-edge repair on forward stroke volume in atrial and ventricular secondary mitral regurgitation.

Clinical research in cardiology : official journal of the German Cardiac Society·2026

Same author

A human cardiomyocyte screen identifies optimized lipid nanoparticles for in vivo cardiac gene editing.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

Digitoxin in heart failure with reduced ejection fraction according to atrial fibrillation status: the DIGIT-HF trial.

European heart journal·2026

Same author

Atrial Fibrillation Increases Proarrhythmic Mechanisms in the Ventricle.

JACC. Basic to translational science·2026

Search research articles

Related Experiment Video

Updated: Jun 13, 2025

CRISPR-Cas9-Mediated Precise Knock-In Edits in Zebrafish Hearts

CRISPR-Cas9-Mediated Precise Knock-In Edits in Zebrafish Hearts

Published on: September 13, 2022

Gene editing in common cardiovascular diseases.

Anna-Maria Lauerer¹, Xurde M Caravia², Lars S Maier¹

¹Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.

Pharmacology & Therapeutics

|September 16, 2024

Summary

This summary is machine-generated.

CRISPR-Cas9 gene editing shows promise for cardiovascular diseases by correcting mutations or disrupting pathogenic pathways. Challenges include delivery and immune response, but it offers a novel therapeutic avenue.

Keywords:

Acquired cardiovascular disease CRISPR-Cas9 genome editing CaMKIIδ Cardiomyopathy Translational cardiology

More Related Videos

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice

Published on: August 2, 2018

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

Related Experiment Videos

Last Updated: Jun 13, 2025

CRISPR-Cas9-Mediated Precise Knock-In Edits in Zebrafish Hearts

CRISPR-Cas9-Mediated Precise Knock-In Edits in Zebrafish Hearts

Published on: September 13, 2022

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice

Published on: August 2, 2018

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

Area of Science:

Biotechnology
Genetics
Cardiology

Background:

Cardiovascular diseases (CVDs) are a major global health burden, with current treatments having limitations like side effects and short-term efficacy.
Novel therapeutic strategies are essential to address the high morbidity and mortality associated with CVDs.
CRISPR-Cas9 genome editing presents a promising new approach for treating cardiovascular conditions.

Purpose of the Study:

To review CRISPR-Cas9 gene editing approaches for cardiovascular diseases.
To discuss the advantages and disadvantages of different gene editing strategies.
To outline the opportunities and challenges in applying CRISPR-Cas9 for CVD treatment.

Main Methods:

Review of current literature on CRISPR-Cas9 applications in cardiovascular research.
Analysis of gene editing strategies for correcting hereditary mutations and disrupting pathogenic signaling cascades.
Discussion of delivery methods and potential immune responses related to CRISPR-Cas9 components.

Main Results:

CRISPR-Cas9 can correct rare hereditary mutations causing CVDs.
Gene editing can disrupt common pathogenic signaling pathways, offering a more generalizable approach.
Challenges include optimizing editing efficiency, delivery systems, and managing immune responses.

Conclusions:

CRISPR-Cas9 gene editing holds significant potential for treating cardiovascular diseases.
Targeting common pathogenic pathways offers broader applicability than correcting rare mutations.
Further research is needed to overcome delivery and immunogenicity challenges for clinical translation.